All Title Author
Keywords Abstract

Nutrients  2012 

The Use of Fish Oil Lipid Emulsion in the Treatment of Intestinal Failure Associated Liver Disease (IFALD)

DOI: 10.3390/nu4121828

Keywords: ?parenteral nutrition, pediatrics, lipid emulsions, intestinal failure-related liver disease, fish oil

Full-Text   Cite this paper   Add to My Lib


Since 2004, fish oil based lipid emulsions have been used in the treatment of intestinal failure associated liver disease, with a noticeable impact on decreasing the incidence of morbidity and mortality of this often fatal condition. With this new therapy, however, different approaches have emerged as well as concerns about potential risks with using fish oil as a monotherapy. This review will discuss the experience to date with this lipid emulsion along with the rational for its use, controversies and concerns.


[1]  Dudrick, S.J.; Wilmore, D.W.; Vars, H.M.; Rhoads, J.E. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery 1968, 64, 134–142.
[2]  Squires, R.H.; Duggan, C.; Teitelbaum, D.H.; Wales, P.W.; Balint, J.; Venick, R.; Rhee, S.; Sudan, D.; Mercer, D.; Martinez, J.A.; et al. Natural history of pediatric intestinal failure: Initial report from the pediatric intestinal failure consortium. J. Pediatr. 2012, 161, 723–728, doi:10.1016/j.jpeds.2012.03.062.
[3]  Quiros-Tejeira, R.E.; Ament, M.E.; Reyen, L.; Herzog, F.; Merjanian, M.; Olivares-Serrano, N.; Vargas, J.H. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: A 25-year experience. J. Pediatr. 2004, 145, 157–163, doi:10.1016/j.jpeds.2004.02.030.
[4]  Willis, T.C.; Carter, B.A.; Rogers, S.P.; Hawthorne, K.M.; Hicks, P.D.; Abrams, S.A. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J. Parenter. Enteral Nutr. 2010, 34, 32–37, doi:10.1177/0148607109332772.
[5]  Chan, S.; McCowen, K.C.; Bistrian, B.R.; Thibault, A.; Keane-Ellison, M.; Forse, R.A.; Babineau, T.; Burke, P. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery 1999, 126, 28–34, doi:10.1067/msy.1999.98925.
[6]  Diamanti, A.; Basso, M.S.; Castro, M.; Calce, A.; Pietrobattista, A.; Gambarara, M. Prevalence of life-threatening complications in pediatric patients affected by intestinal failure. Transplant. Proc. 2007, 39, 1632–1633, doi:10.1016/j.transproceed.2007.02.083.
[7]  Andorsky, D.J.; Lund, D.P.; Lillehei, C.W.; Jaksic, T.; Dicanzio, J.; Richardson, D.S.; Collier, S.B.; Lo, C.; Duggan, C. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J. Pediatr. 2001, 139, 27–33, doi:10.1067/mpd.2001.114481.
[8]  Beath, S.V.; Davies, P.; Papadopoulou, A.; Khan, A.R.; Buick, R.G.; Corkery, J.J.; Gornall, P.; Booth, I.W. Parenteral nutrition-related cholestasis in postsurgical neonates: Multivariate analysis of risk factors. J. Pediatr. Surg. 1996, 31, 604–606, doi:10.1016/S0022-3468(96)90507-2.
[9]  Christensen, R.D.; Henry, E.; Wiedmeier, S.E.; Burnett, J.; Lambert, D.K. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J. Perinatol. 2007, 27, 284–290.
[10]  Burr, G.O.; Burr, M.M. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 1929, 82, 230–234.
[11]  Holman, R.T. The ratio of trienoic: Tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J. Nutr. 1960, 70, 405–410.
[12]  Connor, W.E. Pathogenesis and frequency of essential fatty acid deficiency during total parenteral nutrition. Ann. Intern. Med. 1975, 83, 895–896.
[13]  Tashiro, T.; Ogata, H.; Yokoyama, H.; Mashima, Y.; Iwasaki, I. The effect of fat emulsion of essential fatty acid deficiency during intravenous hyperalimentation in pediatric patients. J. Pediatr. Surg. 1975, 10, 203–213, doi:10.1016/0022-3468(75)90280-8.
[14]  Friedman, A.; Moe, S. Review of the effects of omega-3 supplementation in dialysis patients. Clin. J. Am. Soc. Nephrol. 2006, 1, 182–192, doi:10.2215/CJN.00740805.
[15]  Smit, E.N.; Muskiet, F.A.; Boersma, E.R. The possible role of essential fatty acids in the pathophysiology of malnutrition: A review. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71, 241–250.
[16]  Holman, R. Essential fatty acid deficiency. Prog. Chem. Fats Other Lipids 1971, 9, 275–348, doi:10.1016/0079-6832(71)90030-9.
[17]  Mohrhauer, H.; Holman, R.T. The effect of dose level of essential fatty acids upon fatty acid composition of the rat liver. J. Lipid Res. 1963, 4, 151–159.
[18]  Clarke, S.D.; Jump, D.B. Dietary polyunsaturated fatty acid regulation of gene transcription. Annu. Rev. Nutr. 1994, 14, 83–98, doi:10.1146/
[19]  Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114, 147–152.
[20]  Jump, D.B. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipidol. 2008, 19, 242–247, doi:10.1097/MOL.0b013e3282ffaf6a.
[21]  Wang, Y.; Botolin, D.; Christian, B.; Busik, J.; Xu, J.; Jump, D.B. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J. Lipid Res. 2005, 26, 706–715.
[22]  Xu, H.E.; Lambert, M.H.; Montana, V.G.; Parks, D.J.; Blanchard, S.G.; Brown, P.J.; Sternbach, D.D.; Lehmann, J.M.; Wisely, G.B.; Willson, T.M.; Kliewer, S.A.; Milburn, M.V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 1999, 3, 397–403, doi:10.1016/S1097-2765(00)80467-0.
[23]  Kliewer, S.A.; Mangelsdorf, D.J. Fibroblast growth factor 21: From pharmacology to physiology. Am. J. Clin. Nutr. 2010, 91, 254S–257S, doi:10.3945/ajcn.2009.28449B.
[24]  Inagaki, T.; Dutchak, P.; Zhao, G.; Ding, X.; Gautron, L.; Parameswara, V.; Li, Y.; Goetz, R.; Mohammadi, M.; Esser, V.; et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5, 415–425.
[25]  Park, Y.; Harris, W. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res. 2003, 44, 455–463, doi:10.1194/jlr.M200282-JLR200.
[26]  Fisher, E.A.; Williams, K.J. Autophagy of an oxidized, aggregated protein beyond the ER: A pathway for remarkably late-stage quality control. Autophagy 2008, 4, 721–723.
[27]  Brodsky, J.L.; Fisher, E.A. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol. Metab. 2008, 19, 254–259, doi:10.1016/j.tem.2008.07.002.
[28]  Ginsberg, H.N.; Fisher, E.A. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J. Lipid Res. 2009, 50, S162–S166, doi:10.1194/jlr.R800090-JLR200.
[29]  Jump, D.B.; Botolin, D.; Wang, Y.; Xu, J.; Demeure, O.; Christian, B. Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem. Phys. Lipids 2008, 153, 3–13, doi:10.1016/j.chemphyslip.2008.02.007.
[30]  Das, U.N. Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnol. J. 2006, 1, 420–439.
[31]  Dichtl, W.; Ares, M.P.; Jonson, A.N.; Jovinge, S.; Pachinger, O.; Giachelli, C.M.; Hamsten, A.; Eriksson, P.; Nilsson, J. Linoleic acid-stumulated vascular adhesion molecule-1 expression in endothelial cells depends on nuclear factor-kappa B activation. Metabolism 2002, 51, 327–333.
[32]  Park, H.J.; Lee, Y.W.; Hennig, B.; Toberek, M. Linoleic acid-induced VCAM-1 expression in human microvascular endothelial cells is mediated by the NF-kappa B-dependent pathway. Nutr. Cancer 2001, 41, 126–134.
[33]  Calder, P. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77, 327–335, doi:10.1016/j.plefa.2007.10.015.
[34]  Wall, R.; Ross, R.P.; Fitzgerald, G.F.; Stanton, C. Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev. 2010, 68, 280–289, doi:10.1111/j.1753-4887.2010.00287.x.
[35]  Sijben, J.W.C.; Calder, P.C. Differential immunomodulation with long chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 2007, 66, 237–259.
[36]  Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Klaus, L.; Zeldin, D.C.; Liao, J.K. Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids. Science 1999, 285, 1276–1279, doi:10.1126/science.285.5431.1276.
[37]  Spector, A.A.; Fang, X.; Snyder, G.D.; Weintraub, N.L. Epoxyeicosatrienoic Acids (EETs): Metabolism and Biochemical Function. Prog. Lipid Res. 2004, 43, 55–90, doi:10.1016/S0163-7827(03)00049-3.
[38]  Cleland, L.G.; James, M.J.; Proudman, S.M. The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003, 63, 845–853, doi:10.2165/00003495-200363090-00001.
[39]  Bagga, D.; Wang, L.; Farias-Eisner, R.; Glaspy, J.A.; Reddy, S.T. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. USA 2003, 100, 1751–1756.
[40]  Bellenger, J.; Bellenger, S.; Clement, L.; Mandard, S.; Diot, C.; Poisson, J.P.; Narce, M. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase gene 1 gene expression in the SHR model of genetic hypertension. FASEB J. 2004, 18, 773–775.
[41]  Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin Sensitizing Effects. Cell 2010, 142, 687–698, doi:10.1016/j.cell.2010.07.041.
[42]  Zhao, Y.; Joshi-Barve, S.; Barve, S.; Chen, L.H. Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-kB activation. J. Am. Coll. Nutr. 2004, 23, 71–78.
[43]  Calder, P.C. Mechanisms of Action of (n-3) Fatty Acids. J. Nutr. 2012, 142, 592–599, doi:10.3945/jn.111.155259.
[44]  Leaf, A.; Weber, P.C. Cardiovascular effects of n-3 fatty acids. N. Engl. J. Med. 1988, 318, 549–557, doi:10.1056/NEJM198803033180905.
[45]  Schmidt, E.B.; Dyerberg, J. Omega-3 fatty acids. Current status in cardiovascular medicine. Drugs 1994, 47, 405–424, doi:10.2165/00003495-199447030-00003.
[46]  Grimminger, F.; Wahn, H.; Mayer, K.; Kiss, L.; Walmrath, D.; Seeger, W. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: Relation to 4-series versus 5-series leukotriene generation. Am. J. Respir. Crit. Care Med. 1997, 155, 513–519.
[47]  Lee, T.H.; Hoover, R.L.; Williams, J.D.; Sperling, R.I.; Ravalese, J., III; Spur, B.W.; Robinson, D.R.; Corey, E.J.; Lewis, R.A.; Austen, K.F. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med. 1985, 312, 1217–1224.
[48]  Levy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid mediator class switching during acute inflammation: Signals in resolution. Nat. Immunol. 2001, 2, 612–619.
[49]  Serhan, C.N.; Hong, S.; Gronert, K.; Colgan, S.P.; Devchand, P.R.; Mirick, G.; Moussignac, R.L. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 8, 1025–1037.
[50]  Bannenberg, G.L.; Chiang, N.; Ariel, A.; Arita, M.; Tjonahen, E.; Gotlinger, K.H.; Hong, S.; Serhan, C.N. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol. 2005, 174, 4345–4355.
[51]  Connor, K.M.; SanGiovanni, J.P.; Lofqvist, C.; Aderman, C.M.; Chen, J.; Higuchi, A.; Hong, S.; Pravda, E.A.; Majchrzak, S.; Carper, D.; et al. Increased dietary intake of omega-3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 2007, 13, 868–873.
[52]  Seki, H.; Fukunaga, K.; Arita, M.; Nakanishi, H.; Taguchi, R.; Miyasho, T.; Takamiya, R.; Asano, K.; Ishizaka, A.; Takeda, J.; Levy, B.D. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 2010, 184, 836–843.
[53]  Duffield, J.S.; Hong, S.; Vaidya, V.S.; Lu, Y.; Fredman, G.; Serhan, C.N.; Bonventre, J.V. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 2006, 177, 5902–5911.
[54]  Recchiuti, A.; Krishnamoorthy, S.; Fredman, G.; Chiang, N.; Serhan, C.N. MicroRNAs in resolution of acute inflammation: Identification of novel resolvin D1-miRNA circuits. FASEB J. 2011, 25, 544–560.
[55]  Xu, Z.Z.; Zhang, L.; Liu, T.; Park, J.Y.; Berta, T.; Yang, R.; Serhan, C.N.; Ji, R.R. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 2010, 16, 592–597.
[56]  Gonzalez-Periz, A.; Horrillo, R.; Ferre, N.; Gronert, K.; Dong, B.; Moran-Salvador, E.; Titos, E.; Martinez-Clemente, M.; Lopez-Parra, M.; Arroyo, V.; Claria, J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J. 2009, 6, 1946–1957.
[57]  Vanek, V.W.; Seidner, D.L.; Allen, P.; Bistrian, B.; Collier, S.; Gura, K.; Miles, J.M.; Valentine, C.J.; Kochevar, M. Novel Nutrient Task Force, Intravenous Fat Emulsions Workgroup; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr. Clin. Pract. 2012, 27, 150–192.
[58]  Wanten, G.J.; Calder, P.C. Immune modulation by parenteral lipid emulsions. Am. J. Clin. Nutr. 2007, 85, 1171–1184.
[59]  Seidner, D.L.; Mascioli, E.A.; Istfan, N.W.; Porter, K.A.; Selleck, K.; Blackburn, G.L.; Bistrian, B.R. Effects of long chain triglyceride emulsions on reticuloendothelial system function in humans. JPEN J. Parenter. Enteral Nutr. 1989, 13, 614–619.
[60]  Battistella, F.D.; Widergren, J.T.; Anderson, J.T.; Siepler, J.K.; Weber, J.C.; MacColl, K. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J. Trauma 1997, 43, 52–60, doi:10.1097/00005373-199707000-00013.
[61]  Cober, M.P.; Teitelbaum, D.H. Prevention of parenteral nutrition-associated liver disease: Lipid minimization. Curr. Opin. Organ.Transplant. 2010, 15, 330–333, doi:10.1097/MOT.0b013e328338c2da.
[62]  Meisel, J.A.; Le, H.D.; de Meijer, V.E.; Nose, V.; Gura, K.M.; Mulkern, R.V.; Akhavan Sharif, M.R.; Puder, M. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J. Pediatr. Surg. 2011, 46, 666–673.
[63]  Driscoll, D.F. Lipid injectable emulsions: 2006. Nutr. Clin. Pract. 2006, 21, 381–386, doi:10.1177/0115426506021004381.
[64]  Freund, H.R. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. Nutrition 1991, 7, 1–6.
[65]  Greenberg, G.R.; Wolman, S.L.; Christofides, N.D.; Bloom, S.R.; Jeejeebhoy, K.N. Effect of total parenteral nutrition on gut hormone release in humans. Gastroenterology 1981, 80, 988–993.
[66]  Yeh, S.L.; Chen, W.J.; Huang, P.C. Effects of L-glutamine on induced hepatosteatosis in rats receiving total parenteral nutrition. J. Formos. Med. Assoc. 1995, 94, 593–599.
[67]  Kubota, A.; Yonekura, T.; Hoki, M.; Oyanagi, H.; Kawahara, H.; Yagi, M.; Imura, K.; Iiboshi, Y.; Wasa, K.; Kamata, S.; Okada, A. Total parenteral nutrition-associated intrahepatic cholestasis in infants: 25 years’ experience. J. Pediatr. Surg. 2000, 35, 1049–1051, doi:10.1053/jpsu.2000.7769.
[68]  Moss, R.L.; Das, J.B.; Ansari, G.; Raffensperger, J.G. Hepatobiliary dysfunction during total parenteral nutrition is caused by infusate, not the route of administration. J. Pediatr. Surg. 1993, 28, 391–397.
[69]  Day, C.P.; James, O.F.W. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842–845.
[70]  Kaminski, D.L.; Adams, A.; Jellinek, M. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery 1980, 88, 93–100.
[71]  Hultin, M.; Carneheim, C.; Rosenqvist, K.; Olivecrona, T. Intravenous lipid emulsions: Removal mechanisms as compared to chylomicrons. J. Lipid Res. 1995, 36, 2174–2184.
[72]  Li, S.J.; Nussbaum, M.S.; McFadden, D.W.; Dayal, R.; Fischer, J.E. Reversal of hepatic steatosis in rats by addition of glucagon to total parenteral nutrition (TPN). J. Surg. Res. 1989, 46, 557–566, doi:10.1016/0022-4804(89)90020-6.
[73]  Rangel, S.J.; Calkins, C.M.; Cowles, R.A.; Barnhart, D.C.; Huang, E.Y.; Abdullah, F.; Arca, M.J.; Teitelbaum, D.H. 2011 American Pediatric Surgical Association Outcomes and Clinical Trials Committee. Parenteral nutrition-associated cholestasis: An American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J. Pediatr. Surg. 2012, 47, 225–240.
[74]  Qi, K.; Al-Haideri, M.; Seo, T.; Carpentier, Y.A.; Deckelbaum, R.J. Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions. JPEN J. Parenter. Enteral Nutr. 2003, 27, 58–64.
[75]  Feldstein, A.E.; Canbay, A.; Angulo, P.; Taniai, M.; Burgart, L.J.; Lindor, K.D.; Gores, G.J. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125, 437–443.
[76]  Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25, 4–7, doi:10.1016/
[77]  Ruan, H.; Lodish, H.F. Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003, 14, 447–455, doi:10.1016/S1359-6101(03)00052-2.
[78]  Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221–1231, doi:10.1056/NEJMra011775.
[79]  Li, H.; Miyahara, T.; Tezuka, Y.; Tran, Q.L.; Seto, H.; Kadota, S. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol. Pharm. Bull. 2003, 26, 110–111.
[80]  Feingold, K.R.; Soued, M.; Grunfeld, C. Tumor necrosis factor stimulates DNA synthesis in the liver of intact rats. Biochem. Biophys. Res. Commun. 1988, 153, 576–582.
[81]  Feldstein, A.E.; Canbay, A.; Guicciardi, M.E.; Higuchi, H.; Bronk, S.F.; Gores, G.J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 2003, 39, 978–983, doi:10.1016/S0168-8278(03)00460-4.
[82]  Mullick, F.G.; Moran, C.A.; Ishak, K.G. Total parenteral nutrition: A histopathologic analysis of the liver changes in 20 children. Mod. Pathol. 1994, 7, 190–194.
[83]  Kaufman, S.S.; Pehlivanova, M.; Fennelly, E.M.; Rekhtman, Y.M.; Gondolesi, G.E.; Little, C.A.; Matsumoto, C.S.; Fishbein, T.M. Predicting liver failure in parenteral nutrition-dependent short bowel syndrome of infancy. J. Pediatr. 2010, 156, 580–585.e1, doi:10.1016/j.jpeds.2009.11.002.
[84]  Nehra, D.; Fallon, E.M.; Puder, M. The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg. Clin. North Am. 2011, 91, 543–563.
[85]  Goulet, O.; Joly, F.; Corriol, O.; Colomb-Jung, V. Some new insights in intestinal failure-associated liver disease. Curr. Opin. Organ. Transplant. 2009, 14, 256–261.
[86]  Keim, N.L.; Mares-Perlman, J.A. Development of hepatic steatosis and essential fatty acid deficiency in rats with hypercaloric, fat-free parenteral nutrition. J. Nutr. 1984, 114, 1807–1815.
[87]  Goheen, S.C.; Larkin, E.C.; Rao, G.A. Severe fatty liver in rats fed a fat-free ethanol diet, and its prevention by small amounts of dietary arachidonate. Lipids 1983, 18, 285–290, doi:10.1007/BF02534703.
[88]  Javid, P.; Greene, A.; Garza, J.; Gura, K.; Alwayn, I.P.; Voss, S.; Nose, V.; Satchi-Fainaro, R.; Zausche, B.; Mulkern, R.V.; Jaksic, T.; Bistrian, B.; Folkman, J.; Puder, M. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J. Pediatr. Surg. 2005, 40, 1446–1453, doi:10.1016/j.jpedsurg.2005.05.045.
[89]  Xu, Z.; Harvey, K.A.; Pavlina, T.; Dutot, G.; Hise, M.; Zaloga, G.P.; Siddiqui, R.A. Steroidal compounds in commercial parenteral lipid emulsions. Nutrients 2012, 4, 904–921, doi:10.3390/nu4080904.
[90]  Ostlund, R.E., Jr. Phytosterols in human nutrition. Annu. Rev. Nutr. 2002, 22, 533–549, doi:10.1146/annurev.nutr.22.020702.075220.
[91]  Clayton, P.T.; Whitfield, P.; Iyer, K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition 1998, 14, 158–164.
[92]  Salen, G.; Ahrens, E.H., Jr.; Grundy, S.M. Metabolism of beta-sitosterol in man. J. Clin. Invest. 1970, 49, 952–967, doi:10.1172/JCI106315.
[93]  Repa, J.J.; Berge, K.E.; Pomajzl, C.; Richardson, J.A.; Hobbs, H.; Mangelsdorf, D.J. Regulation of ATP binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 2002, 277, 18793–18800.
[94]  Ostlund, R.E., Jr.; McGill, J.B.; Zeng, C.M.; Covey, D.F.; Stearns, J.; Stenson, W.F.; Spilburg, C.A. Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans. Am. J. Physiol. Endocrinol. Metab. 2002, 282, E911–E916.
[95]  Van Aerde, J.E.; Duerksen, D.R.; Gramlich, L.; Meddings, J.B.; Chan, G.; Thomson, A.B.; Clandinin, M.T. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr. Res. 1999, 45, 202–208.
[96]  Iyer, K.R.; Spitz, L.; Clayton, P. BAPS Prize Lecture: New insight into mechanisms of parenteral nutrition-associated cholestasis: Role of plant sterols. British Association of Paediatric Surgeons. J. Pediatr. Surg. 1998, 33, 1–6, doi:10.1016/S0022-3468(98)90349-9.
[97]  Clayton, P.T.; Bowron, A.; Mills, K.A.; Massoud, A.; Casteels, M.; Milla, P.J. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology 1993, 105, 1806–1813.
[98]  Ling, W.H.; Jones, P.J. Dietary phytosterols: A review of metabolism, benefits and side effects. Life Sci. 1995, 57, 195–206.
[99]  Carter, B.A.; Taylor, O.A.; Prendergast, D.R.; Zimmerman, T.L.; Von Furstenberg, R.; Moore, D.D.; Karpen, S.J. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res. 2007, 62, 301–306, doi:10.1203/PDR.0b013e3181256492.
[100]  Shefer, S.; Salen, G.; Nguyen, L.; Batta, A.K.; Packin, V.; Tint, G.S.; Hauser, S. Competitive inhibition of bile acid synthesis by endogenous cholestanol and sitosterol in sitosterolemia with xanthomatosis Effect on cholesterol 7 alpha-hydroxylase. J. Clin. Invest. 1988, 82, 1833–1839.
[101]  Boberg, K.M.; Akerlund, J.E.; Bj?rkhem, I. Effect of sitosterol on the rate-limiting enzymes in cholesterol synthesis and degradation. Lipids 1989, 24, 9–12, doi:10.1007/BF02535257.
[102]  Liu, Y.; Binz, J.; Numerick, M.J.; Dennis, S.; Luo, G.; Desai, B.; MacKenzie, K.I.; Mansfield, T.A.; Kliewer, S.A.; Goodwin, B.; Jones, S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 2003, 112, 1678–1687.
[103]  Wanten, G.; Beunk, J.; Naber, A.; Swinkels, D. Tocopherol isoforms in parenteral lipid emulsions and neutrophil activation. Clin. Nutr. 2002, 21, 417–422, doi:10.1054/clnu.2002.0570.
[104]  Ames, B.N.; Shigenaga, K.; Hagen, T.M. Oxidants, antioxidants and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 1993, 90, 7915–7922.
[105]  Kohen, R.; Nyska, A. Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification. Toxicol. Pathol. 2002, 30, 620–650, doi:10.1080/01926230290166724.
[106]  Hong, L.; Wang, X.; Wu, J.; Cai, W. Mitochondria-initiated apoptosis triggered by oxidative injury play a role in total parenteral nutrition—associated liver dysfunction in infant rabbit model. J. Pediatr. Surg. 2009, 44, 1712–1718, doi:10.1016/j.jpedsurg.2009.04.002.
[107]  Chung, M.Y.; Yeung, S.F.; Park, H.J.; Volek, J.S.; Bruno, R.S. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J. Nutr. Biochem. 2010, 21, 1200–1206, doi:10.1016/j.jnutbio.2009.10.006.
[108]  Soden, J.S.; Devereaux, M.W.; Haas, J.E.; Gumpricht, E.; Dahl, R.; Gralla, J.; Traber, M.G.; Sokol, R.J. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology 2007, 46, 485–495.
[109]  Becvarova, I.; Saker, K.E.; Swecker, W.S., Jr.; Troy, G.C. Peroxidative protection of parenteral admixture by D-alpha-tocopherol. Vet. Ther. 2005, 6, 280–290.
[110]  Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, M.; Bass, M.; Neushwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Eng. J. Med. 2010, 365, 1675–1685.
[111]  Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011, 305, 1659–1668.
[112]  Strijbosch, R.A.M.; Lee, S.; Arsenault, D.A.; Andersson, C.; Gura, K.M.; Bistrian, B.R.; Puder, M. Fish oil prevents essential fatty acid deficiency and enhances growth: Clinical and biochemical implications. Metabolism 2008, 57, 698–707, doi:10.1016/j.metabol.2008.01.008.
[113]  De Meijer, V.E.; Le, H.; Meisel, J.A.; Gura, K.M.; Puder, M. Parenteral fish oil as a monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J. Pediatr. Gastroenterol. Nutr. 2010, 50, 212–218, doi:10.1097/MPG.0b013e3181bbf51e.
[114]  Le, H.D.; de Meijer, V.E.; Robinson, E.; Zurakowski, D.; Potemkin, A.K.; Arsenault, D.A.; Fallon, E.M.; Malkan, A.; Bistrian, B.R.; Gura, K.M.; Puder, M. Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am. J. Clin. Nutr. 2011, 94, 749–758, doi:10.3945/ajcn.110.008557.
[115]  Diamond, I.R.; Pencharz, P.B.; Feldman, B.M.; Ling, S.C.; Moore, A.M.; Wales, P.W. Novel lipid-based approaches to pediatric intestinal failure-associated liver disease. Arch. Pediatr. Adolesc. Med. 2012, 166, 473–478, doi:10.1001/archpediatrics.2011.1896.
[116]  Nehra, D.; Le, H.D.; Fallon, E.M.; Carlson, S.J.; Woods, D.; White, Y.A.; Pan, A.H.; Guo, L.; Rodig, S.J.; Tilly, J.L.; Rueda, B.R.; Puder, M. Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids. Aging Cell 2012, 11, 1046–1054.
[117]  Le, H.D.; Meisel, J.A.; de Meijer, V.E.; Fallon, E.M.; Gura, K.M.; Nose, V.; Bistrian, B.R.; Puder, M. Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. JPEN J. Parenter. Enteral. Nutr. 2012, 36, 431–441.
[118]  Gura, K.M.; Parsons, S.K.; Bechard, L.J.; Henderson, T.; Dorsey, M.; Phipatanakul, W.; Duggan, C.; Puder, M.; Lenders, C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin. Nutr. 2005, 24, 839–847, doi:10.1016/j.clnu.2005.05.020.
[119]  Gura, K.M.; Duggan, C.P.; Collier, S.B.; Jennings, R.W.; Folkman, J.; Bistrian, B.R.; Puder, M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: Implications for future management. Pediatrics 2006, 118, e197–e201, doi:10.1542/peds.2005-2662.
[120]  Gura, K.M.; Lee, S.; Valim, C.; Zhou, J.; Kim, S.; Modi, B.P.; Arsenault, D.A.; Strijbosch, R.A.; Lopes, S.; Duggan, C.; Puder, M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008, 121, 678–686.
[121]  Puder, M.; Valim, C.; Meisel, J.A.; Le, H.D.; de Meijer, V.E.; Robinson, E.M.; Zhou, J.; Duggan, C.; Gura, K.M. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann. Surg. 2009, 250, 395–402.
[122]  Ekema, G.; Falchetti, D.; Boroni, G.; Tanca, A.R.; Altana, C.; Righetti, L.; Ridella, M.; Gambarotti, M.; Berchich, L. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (Omega-3 fatty acids). J. Pediatr. Surg. 2008, 43, 1191–1195, doi:10.1016/j.jpedsurg.2008.01.005.
[123]  Cheung, H.M.; Lam, H.S.; Tam, Y.H.; Lee, K.H.; Ng, P.C. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin. Nutr. 2009, 28, 209–212, doi:10.1016/j.clnu.2009.02.004.
[124]  Strijbosch, R.A.; van den Hoonaard, T.L.; Olieman, J.F.; Escher, J.C.; Alwayn, I.P.; Meijers-Ijsselstijn, H. Fish oil in prolonged parenteral nutrition in children-omega-3-fatty acids have a beneficial effect on the liver. Ned. Tijdschr. Geneeskd. 2010, 154, A2003.
[125]  Calhoun, A.W.; Sullivan, J.E. Omegaven for the treatment of parenteral nutrition associated liver disease: A case study. J. Ky. Med. Assoc. 2009, 107, 55–57.
[126]  Pironi, L.; Colecchia, A.; Guidetti, M.; Belluzzi, A.; D’Errico, A. Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient. e-SPEN 2010, 5, e243–e246.
[127]  Jurewitsch, B.; Gardiner, G.; Naccarato, M.; Jeejeebhoy, K.N. Omega-3-enriched lipid emulsion for liver salvage in parenteral nutrition induced cholestasis in the adult patient. JPEN J. Parenter. Enteral Nutr. 2011, 35, 386–390, doi:10.1177/0148607110382023.
[128]  Burns, D.L.; Gill, B.M. Reversal of parenteral nutrition-associated liver disease with fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 2012. in press.
[129]  Mallah, H.S.; Brown, M.R.; Rossi, T.M.; Block, R.C. Parenteral fish oil-associated burr cell anemia. J. Pediatr. 2010, 156, 324–326, doi:10.1016/j.jpeds.2009.07.062.
[130]  Grahn, E.P.; Dietz, A.A.; Stefani, S.S.; Donnelly, W.J. Burr cells, hemolytic anemia and cirrhosis. Am. J. Med. 1968, 45, 78–87.
[131]  Soden, J.S.; Lovell, M.A.; Brown, K.; Partrick, D.A.; Sokol, R.J. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible failure. J. Pediatr. 2010, 156, 327–331.
[132]  Dimmitt, R.A.; Leadford, A.L.; Bartle, D.; Wilkinson, L.; Manimaran, V.; Harmon, M. Impact of Omega-3 Fatty Acids on Liver Function Test and Liver Histology in Children with Intestinal Failure Associated Intestinal Disease; Pediatric Academic Society: Boston, MA, USA, 2012. E-PAS2012:3830.366.
[133]  Diamond, I.R.; Sterescu, A.; Pencharz, P.B.; Kim, J.H.; Wales, P.W. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 2009, 48, 209–215, doi:10.1097/MPG.0b013e318182c8f6.
[134]  Muhammed, R.; Bremner, R.; Protheroe, S.; Johnson, T.; Holden, C.; Murphy, S.M. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 797–802, doi:10.1097/MPG.0b013e3182447daf.
[135]  Tomsits, E.; Pataki, M.; T?lgyesi, A.; Fekete, G.; Rischak, K.; Szollár, L. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: A randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 2010, 51, 514–521, doi:10.1097/MPG.0b013e3181de210c.
[136]  Goulet, O.; Antébi, H.; Wolf, C.; Talbotec, C.; Alcindor, L.G.; Corriol, O.; Lamor, M.; Colomb-Jung, V. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: A single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 2010, 34, 485–495, doi:10.1177/0148607110363614.
[137]  Colomb, V.; Jobert-Giraud, A.; Lacaille, F.; Goulet, O.; Fournet, J.C.; Ricour, C. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J. Parenter. Enteral. Nutr. 2000, 24, 345–350.
[138]  Rubinos, L.H.; Ruth, J.S.; Hawthorne, K.; Abrams, S.A. Reducing Soy-Based Lipid ConcentrationMay Not Prevent the Need for Omega-3 Therapy in Parenteral Nutrition Associated Cholestasis; Pediatric Academic Society: Boston, MA, USA, 2012. E-PAS2012:3830.369.
[139]  Nehra, D.; Fallon, E.M.; Carlson, S.J.; Potemkin, A.K.; Hevelone, N.D.; Mitchell, P.D.; Gura, K.M.; Puder, M. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J. Parenter. Enteral Nutr. 2012. in press.


comments powered by Disqus